Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE, Inc. (NASDAQ: BIOL) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Investor Conference from January 10-13, 2022. The company's President and CEO, John Beaver, will deliver a presentation and conduct virtual meetings with investors. A pre-recorded presentation will be available starting January 10, 2022, at 7 am ET. Interested parties can schedule one-on-one meetings by contacting BIOLASE's investor relations team via email.
BIOLASE develops and markets dental laser systems, offering innovative technology designed to enhance dental procedures.
BIOLASE, Inc. (NASDAQ: BIOL) announced it received a 180-day extension from Nasdaq to comply with the minimum bid price requirement, now due by May 23, 2022. The company must close at or above $1.00 for 10 consecutive trading days to regain compliance. Additionally, BIOLASE amended its senior secured term loan with SWK Funding LLC, extending the maturity to May 31, 2025, and reducing the interest rate by 200 basis points. CEO John Beaver highlighted this extension as an opportunity to demonstrate growth, while a SWK Holdings CEO noted strong operating traction and market acceptance of BIOLASE's dental lasers.
BIOLASE, Inc. (NASDAQ: BIOL), a leader in dental laser technology, announced its participation in the Benchmark Company Discovery One-on-One Virtual Investor Conference on December 2, 2021. The event will run from 8:00 a.m. to 4:30 p.m. Eastern Time and will include opportunities for individual meetings with investors. BIOLASE develops advanced laser systems used in dentistry, with over 41,200 systems sold globally. The conference is expected to attract more than 150 institutional investors and around 50 presenting companies.
BIOLASE, Inc. (NASDAQ: BIOL) is urging stockholders to vote in favor of a reverse stock split at the upcoming special meeting on November 19, 2021. The amendment aims to maintain the company's listing on The Nasdaq Capital Market and attract institutional investors. The board recommends approval to enhance liquidity, offer equity compensation, and ensure shares are available for future use. Leading proxy advisory firms, including Institutional Shareholder Services and Glass, Lewis & Co., have endorsed this proposal.
BIOLASE, Inc. (NASDAQ: BIOL) reported a 46% increase in net revenue for Q3 2021, totaling $9.5 million. A strong trend continued with 78% of U.S. laser sales from new customers. Laser system sales rose 64%, while consumables revenue grew 21%. Gross margin improved significantly to 51%, up 1,600 basis points. International revenue surged 101%. The company maintains a solid balance sheet with $33.4 million in cash. BIOLASE forecasts Q4 revenue to exceed pre-pandemic figures from 2019.
BIOLASE, Inc. (NASDAQ: BIOL) has launched the Epic Hygiene Academy, aiming to enhance dental hygiene education and patient care through laser technology. This program, available for BIOLASE diode laser users, focuses on empowering hygienists with advanced skills and resources, fostering superior preventive and therapeutic care. The academy will feature mentorship, interactive case reviews, and educational resources. Additionally, BIOLASE is donating an Epic Hygiene laser to Greenville Technical College, emphasizing its commitment to training future hygienists.
BIOLASE, Inc. (NASDAQ: BIOL) will release its third quarter 2021 financial and operating results on November 10, 2021, after U.S. financial markets close. A conference call and webcast will be held at 4:30 p.m. ET to discuss the results and corporate developments. Participants can join via dial-in numbers: (800) 367-2403 for U.S./Canada and (334) 777-6978 internationally, using Conference ID 3599686. The live webcast and an audio archive will be available on the BIOLASE Investor Events Page.
BIOLASE, Inc. (NASDAQ: BIOL) is urging stockholders to vote 'FOR' a proposed reverse stock split at a special meeting on November 19, 2021. This action aims to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share, following a deficiency notification received earlier this year. A successful vote could help attract institutional investors, increase trading liquidity, and enable equity compensation for employees. The reverse stock split will not affect stockholders' percentage ownership.
BIOLASE, Inc. (NASDAQ: BIOL) announces an upcoming Q&A session for investors regarding a special meeting of stockholders on November 19, 2021, at 10:00 am PT. The company will utilize Say Technologies to facilitate investor questions prior to a webcast on October 25, 2021, at 1:00 pm PT. Investors holding BIOL stock as of October 1, 2021, can submit questions until October 19, 2021. More details can be found on BIOLASE's investor page.
BIOLASE, Inc. (NASDAQ: BIOL) and Healthy Smiles for Kids of Orange County are hosting an awareness reception on Sept. 24, from 5:00 p.m. - 7:00 p.m. at the BIOLASE Learning Center in Foothill Ranch, California. The event aims to enhance children's oral health in the community. Attendees can hear testimonials from families and providers utilizing BIOLASE's Waterlase dental lasers. The partnership also includes a donation of a Waterlase i-Plus laser to Healthy Smiles, which has served around 1 million children since its inception.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
